by Raynovich Rod | May 22, 2013 | BIOgraph, Biopharmaceuticals
Biotechs Bounce Back After Deep Dive Unless you were trading at the open today and covered your shorts you could have been whipsawed in a volatile market that had NASDAQ down to the 3425 level. Many biotech stocks recovered today so no technical damage. The IBB was...
by Raynovich Rod | Apr 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost Vertex (VRTX $82), a laggard in the frothy biotech universe rose an astonishing 58% on positive Phase 2 clinical news from its cystic fibrosis drug VX-661. The study showed statistically significant improvement...
by Raynovich Rod | Apr 17, 2013 | Biopharmaceuticals, Macro
Major Sell-Off Early On April 17–Correction is Here with Some Technical Damage Posted 12.15p EDT, Update at 4:56p The rally yesterday was apparently a head fake as a major sell-off resumed today with the NASDAQ down 2.10% and the S&P down 1.7%. The gold free...
by Raynovich Rod | Apr 12, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Biotech and Drug Stocks Remain in the Sweet Spot NAZ Down 0.16% at 3295 at Close A string of market up days was halted today as retail sales and consumer sentiment gave bearish indicators.Commodity stocks were also weak-energy down 1.2%, materials down 1.7%- and there...
by Raynovich Rod | Mar 14, 2013 | Biopharmaceuticals, Macro
Technicals Matter in a MOmentum Market Some important trends are developing in momentum stocks some of which are on in our Life Science Portfolio. As we have written previously many momentum stocks are being driven by media buzz, novel business models and sponsorship...
by Raynovich Rod | Mar 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
FED Fuel Fans Feuer The monetized momentum market rolled on today despite the backdrop of bearish commentary from celebrity pundits and strategists. With the DOW hitting new highs at 14,263 (and forgetting about the 2001 NASDAQ 5000 high which is still 2000 points...
by Raynovich Rod | Feb 26, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and...
by Raynovich Rod | Jan 14, 2013 | BIOgraph
Healthcare Sector Gets Boost from JPMorgan Conference-Large Caps Lag Except CELG Most life science stocks were quiet today after a strong showing during the JPMorgan Healthcare Conference Jan. 7-10. The biotechnology sector was up over 35% in 2012 and usually this...
by Raynovich Rod | Oct 22, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and Gilead (GILD $68.85) up 6%....
by Raynovich Rod | Sep 26, 2012 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip...
